Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 1;42(28):2207–2217. doi: 10.1038/s41388-023-02737-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A Crystal violet staining of parental or tamoxifen-resistant (TAMR) MCF-7 cells grown in the presence of 10 μM tamoxifen (TAM), 100 nM fulvestrant (FUL), or DMSO as a control. B Crystal violet staining of parental or tamoxifen-resistant (TAMR) MCF-7 cells grown in the presence of various concentrations of RMC-6272. C Immunoblot of lysates of MCF-7 TAMR cells treated with Everolimus, INK128 or RMC-6272 for 4 h at indicated doses. Image represents at least two independent experiments. D Mice carrying MCF-7 TAMR orthotopic xenograft tumors were treated with vehicle, fulvestrant, RMC-6272, or the combination for 21 days. n = 7 per group except for vehicle which was n = 6. E Relative change in tumor volume of individual mice at day 21 colored by treatment group. F Single and combination agent dosing in two patient-derived xenograft models derived from ER+ breast cancer patients experiencing acquired resistance to hormone therapies. n = 9 mice for each arm in CTG-1211 and n = 9 for each arm in CTG-1260 except for vehicle group in CTG-1260 which was n = 4 beginning day 9. PI3K pathway mutation and previous patient treatments are indicated. P values based on two-tailed Student’s t-test.